Device for Treating Generalized Anxiety
NCT07819773
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to learn if treatment with the BTL-699-2 device (non-invasive repetitive transcranial magnetic stimulation) can decrease anxiety symptoms in adults (aged 22 years and older) diagnosed with Generalized Anxiety Disorder (GAD). The main questions it aims to answer are: Does the accelerated treatment protocol using the BTL-699-2 device reduce self-reported anxiety symptoms (as measured by the GAD-7 scale) 3 months after the final treatment? What are the safety and side effects associated with the use of the BTL-699-2 device during this accelerated protocol?
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Generalized Anxiety Disorder (GAD)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 22 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- BTL Industries Ltd.
- Last updated on ClinicalTrials.gov
- September 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- Aria Integrative Health · Denver, CO
Illinois · 1
- The Study by AC · Chicago, IL
Indiana · 1
- Cady Wellness Institute · Newburgh, IN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.